<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02977052</url>
  </required_header>
  <id_info>
    <org_study_id>M16OPN</org_study_id>
    <secondary_id>2016-001984-35</secondary_id>
    <secondary_id>CA209-701</secondary_id>
    <nct_id>NCT02977052</nct_id>
  </id_info>
  <brief_title>Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab</brief_title>
  <acronym>OpACIN-neo</acronym>
  <official_title>Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label three-arm phase 2 trial (including a Simon stage 2 design) consisting
      of 90 stage III melanoma patients randomized 1:1:1 to receive either 2 courses 3 mg/kg
      ipilimumab + 1 mg/kg nivolumab every 3 weeks (Arm A), 2 courses 1 mg/kg ipilimumab + 3 mg/kg
      nivolumab every 3 weeks (Arm B), or 2 courses ipilimumab 3 mg/kg, directly followed by 2
      courses nivolumab 3 mg/kg every 2 weeks (Arm C). All three treatment arms are applied prior
      to surgery at week 6, 30 patients per arm. Patients will be stratified according to treatment
      center. An interim analysis will be performed after 13 patients have been included in each
      arm, thus in total 39 patients have been included.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by the frequency of grade 3/4 immune-related adverse events, using CTCAE 4.03</measure>
    <time_frame>During the first 12 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate according to RECIST 1.1</measure>
    <time_frame>At 6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathological response according to central pathological revision, according to pathological response criteria</measure>
    <time_frame>At 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence Free Survival</measure>
    <time_frame>3 years after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of late adverse events using CTCAE 4.03</measure>
    <time_frame>Up to 3 years after treatment initiation until new treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of associations of mutational load, RNA tumor signatures, and tumor educated platelet signatures with tumor immune infiltrates and response</measure>
    <time_frame>At 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Malignant Melanoma Stage III</condition>
  <arm_group>
    <arm_group_label>Arm A: 2 courses ipi 3 + nivo 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2 courses standard combination of ipilimumab 3 mg/kg + nivolumab 1 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: 2 courses ipi 1 + nivo 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2 courses ipilimumab 1 mg/kg + nivolumab 3 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: 2 courses ipi 3 + 2 courses nivo 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 2 courses of ipilimumab 3 mg/kg q3wks, directly followed (&gt; 2 hours and &lt; 24 hours) by 2 courses nivolumab 3 mg/kg every 2 weeks prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Arm A: 2 courses ipi 3 + nivo 1</arm_group_label>
    <arm_group_label>Arm B: 2 courses ipi 1 + nivo 3</arm_group_label>
    <arm_group_label>Arm C: 2 courses ipi 3 + 2 courses nivo 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Arm A: 2 courses ipi 3 + nivo 1</arm_group_label>
    <arm_group_label>Arm B: 2 courses ipi 1 + nivo 3</arm_group_label>
    <arm_group_label>Arm C: 2 courses ipi 3 + 2 courses nivo 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery will be done at 6 weeks</description>
    <arm_group_label>Arm A: 2 courses ipi 3 + nivo 1</arm_group_label>
    <arm_group_label>Arm B: 2 courses ipi 1 + nivo 3</arm_group_label>
    <arm_group_label>Arm C: 2 courses ipi 3 + 2 courses nivo 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood for PBMCs</intervention_name>
    <description>Blood will be taken for translational research on PBMCs</description>
    <arm_group_label>Arm A: 2 courses ipi 3 + nivo 1</arm_group_label>
    <arm_group_label>Arm B: 2 courses ipi 1 + nivo 3</arm_group_label>
    <arm_group_label>Arm C: 2 courses ipi 3 + 2 courses nivo 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsies</intervention_name>
    <description>Biopsies will be taken during screening and at relapse.</description>
    <arm_group_label>Arm A: 2 courses ipi 3 + nivo 1</arm_group_label>
    <arm_group_label>Arm B: 2 courses ipi 1 + nivo 3</arm_group_label>
    <arm_group_label>Arm C: 2 courses ipi 3 + 2 courses nivo 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults at least 18 years of age

          -  World Health Organization (WHO) Performance Status 0 or 1

          -  Cytologically or histologically confirmed resectable stage III melanoma with one or
             more macroscopic lymph node metastases (measurable according to RECIST 1.1), that can
             be biopsied, and no history of in-transit metastases within the last 6 months

          -  No other malignancies, except adequately treated and a cancer-related life-expectancy
             of more than 5 years

          -  Patient willing to undergo triple tumor biopsies and extra blood withdrawal during
             screening and in case of relapse

          -  No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1

          -  No immunosuppressive medications within 6 months prior study inclusion

          -  Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L,
             Neutrophils ≥1.5x109/L, Platelets ≥100 x109/L, Hemoglobin ≥5.5 mmol/L, Creatinine
             ≤1.5x ULN, AST ≤ 1.5 x ULN, ALT ≤ 1.5 x ULN, Bilirubin ≤1.5 X ULN

          -  Normal LDH

          -  Women of childbearing potential (WOCBP) must use appropriate method(s) of
             contra-ception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks
             (30 days plus the time required for nivolumab to undergo five half-lives) after the
             last dose of investigational drug

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the
             start of ipilimumab + nivolumab

          -  Men who are sexually active with WOCBP must use any contraceptive method with a
             failure rate of less than 1% per year. Men receiving nivolumab and who are sexually
             active with WOCBP will be instructed to adhere to contraception for a period of 31
             weeks after the last dose of investigational product

          -  Women who are not of childbearing potential (i.e., who are postmenopausal), or
             surgically sterile as well as azoospermic men do not require contraception

          -  Patient is capable of understanding and complying with the protocol requirements and
             has signed the Informed Consent document.

        Exclusion Criteria:

          -  Distantly metastasized melanoma

          -  History of in-transit metastases within the last 6 months

          -  No measurable lesion according to RECIST 1.1

          -  Subjects with any active autoimmune disease or a documented history of autoimmune
             disease, or history of syndrome that required systemic steroids or immunosuppressive
             medications, except for subjects with vitiligo or resolved childhood asthma/atopy

          -  Prior CTLA-4 or PD-1/PD-L1 targeting immunotherapy

          -  Radiotherapy prior or post-surgery

          -  Patients will be excluded if they test positive for hepatitis B virus surface antigen
             (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or
             chronic infection

          -  Patients will be excluded if they have known history of testing positive for human
             immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)

          -  Allergies and Adverse Drug Reaction

               -  History of allergy to study drug components

               -  History of severe hypersensitivity reaction to any monoclonal antibody

          -  Underlying medical conditions that, in the Investigator's opinion, will make the
             administration of study drug hazardous or obscure the interpretation of toxicity
             determination or adverse events;

          -  Concurrent medical condition requiring the use of immunosuppressive medications, or
             immunosuppressive doses of systemic or absorbable topical corticosteroids;

          -  Use of other investigational drugs before study drug administration 30 days and 5
             half-times before study inclusion

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Blank, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Medical oncologist/researcher</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Blank-de Hoop, Prof.</last_name>
    <phone>+31205122951</phone>
    <email>c.blank@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisette Rozeman, MD</last_name>
    <phone>+31205126281</phone>
    <email>l.rozeman@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gonzalez</last_name>
      <phone>+61299117300</phone>
      <email>Maria.Gonzalez@melanoma.org.au</email>
    </contact>
    <investigator>
      <last_name>Georgina Long</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Hoeller, Prof.</last_name>
      <email>christoph.hoeller@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christoph Hoeller, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <state>NH</state>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Blank-de Hoop, Prof.</last_name>
      <phone>+31205122951</phone>
      <email>c.blank@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lisette Rozeman, MD</last_name>
      <phone>+31205126281</phone>
      <email>l.rozeman@nki.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>S-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Hansson, Prof.</last_name>
      <email>Johan.Hansson@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Leia Ollmar</last_name>
      <email>leia.ollmar@sll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Johan Hansson, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanna Eriksson, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2016</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Neo-adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

